Objective: To develop and validate a two-step enrichment-identification system for circulating tumor cells (CTCs) by improving the isolation by size of tumor cells (ISET) technology and combining it with an immunocytochemistry (ICC) technique.
Introduction
Circulating tumor cells (CTCs) detach from primary or metastatic tumor sites and migrate and infiltrate new sites via the bloodstream [1] . Hence, they can be detected in the peripheral blood of patients with a variety of malignant tumors, thus enabling real-time and minimally-invasive early detection and prognosis of disease malignancy, assessment of therapeutic efficacy, and application of personalized therapy [2] [3] [4] [5] .Most CTCs die before establishing a metastatic lesion due to their short half-life, stress factors, and immune surveillance mechanisms [3, 6] .Because they are low in numbers (about 1-10 cells/10mL of blood), they are challenging to detect by existing detection techniques [7] . Patients with a higher number of CTCs or persistent CTCs show significantly worse prognoses and survival rates [8, 9] .
Pathological examination by tissue biopsy is the gold standard for cancer diagnosis, but it is an invasive method.
In contrast, methods such as the CellSearch TM system (Veridex Corporation, Warren, NJ, USA) [5, 10] and isolating by size of epithelial tumor cells (ISET) (Rare cells Diagnostics, Paris, France) [6, 11] , also known as liquid biopsy methods, are minimally invasive [12] . Combining cell enrichment technology and cell identification technology can increase the sensitivity for CTC detection [6, 13, 14] . Common cell enrichment techniques include immunomagnetic cell sorting technology, microfluidic devices for CTC capture, and cell filtration technology [5, 6, 11, 15, 16] , while cell identification techniques include single-cell sequencing [6, 17] reverse transcriptionpolymerase chain reaction, immunocytochemistry (ICC), and morphological identification [6, 8] .
Immunomagnetic sorting or immunomagnetic separation is based on the recognition of specific antigenic markers on the cell surface, while cell filtration sorts cells by size [11, 16] . The former method does not require cell lysis during screening and enables morphological analysis of the sorted cells, but the expression of nontumor markers or the absence of tumor-specific antigen expression can result in false positives and negatives, respectively. The cell filtration method is simple and inexpensive, allows morphological analysis and counting of the cells, and the isolated CTCs are active. However, this method has poor specificity as CTCs have a wide size range that overlaps with that of white blood cells, which increases the probability of obtaining false positives [6, 7, 13] . ICC detects specific antigens expressed by tumor cells such as epithelial cell adhesion molecule (EpCAM) and cytokeratin (CK)in situ to identify CTCs [5, 11] . This technique enables counting and observing cell morphologies, but it may result in false-negative results due to the instability of tumor cellspecific antigen expression and the heterogeneity of tumor cells between individuals [5] . In addition, not all CTCs isolated are functionally viable [5, 18] . Moreover, there is no consensus definition of epithelial biomarker expression on CTCs [4] , which limits the reliability of existing CTC detection methods.
The Federal Drug Administration (FDA)-approved CellSearch TM system is an early semi-automated detection system that integrates CTC sorting, enrichment, and identification [5, 10] . It has a high specificity as it detects the expression of tumor-specific cell surface antigen markers such as EpCAM and CK. In addition, the cell integrity is preserved, which enables cell counting and morphological examination. It has been successfully used to detect CTCs in various cancers such as metastatic breast cancer and prostate cancer making it the most widely used CTC detection technology on the market [19, 20] .
However, only about 70% of all tumor types express the EpCAM antigen, and not all tumor cells express CK [21] . 
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In addition, some tumor cells undergo epithelial mesenchymal transition (EMT, which affects the expression of the CK marker, in turn affecting CTC detection) [22, 23] .
Since this technique involves the specific identification of tumor-specific antigens, the downregulation of antigen expression reduces the CTC capture efficiency and may give rise to false negatives [5, 24] . Alternative EpCAMbased devices, including IsoFlux [25] , MagSweeper [26] and GILUPI [27] face similar limitations as the CellSearch TM method [16] . Given the aforementioned challenges of the CellSearch TM method, there is an urgent need to develop more reliable methods.
ISET is a cell filtration technique that applies the principle of identifying CTCs based on the significant size differences between tumor cells and blood cells [15] . [29] .
The advantages of ISET include a high CTC detection rate, ease of use, no effect on cell integrity, and a low cost.
However, the lack of a morphological "gold standard" for CTC identification limits the reliability and applicability of this method. In addition, the existing ISET method still has a tendency of filter membrane clogging, primarily by large aggregates of red blood cells and by large-sized white blood cells such as monocytes and large lymphocytes, which makes the filtration process slow and inefficient. Hence, the aim of this study was to optimize the ISET technology and to combine it with ICC to form a novel two-step tumor cell enrichment before drawing blood, and the patient had signed the consent form.
Methods

Patient information
ISET
The ISET device comprising five parts: 1) fixed iron frame,
2) blood sample container, 3) filter with a hydrophobic filter membrane (Millipore), 4) infusion device, and 5) waste liquid cylinder, was first assembled ( Figure 1 ). The gastric cancer 803 cell line was spiked into the PB from healthy volunteers to simulate the PB of tumor patients in a ratio of 200 μL of tumor cell suspension per two PB cells.
The tumor cell suspension was prepared as previously described [30] . The samples were centrifuged at 500 g for 5
min to obtain the blood cells, which were then mixed with a Photograph of the ISET device.
ISET-ICC
The PB from healthy volunteers was spiked into the gastric cancer 803 cell line (10 3 /mL) in a ratio of 200 μL of tumor cell suspension per two PB cells, and this mixture was divided into the experimental and control groups before performing ISET. The samples were centrifuged at 500 g for [24] . If all criteria were satisfied except it was CK8/18/19-negative, it was identified as an EMT-CTC.
Cell wax block-immunohistochemistry (IHC)
ISET-ICC followed by wax block-IHC was performed for EMT-CTC detection. Ten-mL samples of PB from patients with advanced cancer or with no specific disease type were collected and then divided into the experimental and control groups, respectively. One sample was tested with ISET-ICC as previously described in the previous subsection. If EMT-CTCs could be detected by the ISET-ICC technology, another blood sample was taken to make a cell wax block, and further immunohistochemical detection was performed.
This PB sample was first centrifuged at 500 g for 5 min at room temperature to obtain the blood cells, which were transferred into a new 50-mL centrifuge tube and diluted with a 5× volume of RBC lysis buffer. Next, the suspension was incubated with 0.25% Cytoperm/Cytofixreagent for 10 min. The pretreated cell suspension was then filtered using an ISET filter device equipped with a membrane with a 10μm pore size. After filtration, the filter was removed and rinsed three times with 200 µLof PBS, and then it was fixed in 10% neutral formalin for 4-6 h. This was then embedded by conventional dehydration and wax impregnation methods to prepare a cell wax block of one to three 4-μm sections [31] . The sections were solidified in an oven at 60°C for 2 h and were dewaxed with xylene I for 2 h, deoxygenated in xylene II and III for 1 h, and then dewaxed in xylene IV overnight. Next, they were hydrated with gradient alcohol solutions (100%, 100%, 95%, 90%, and 80%) for 5 min each before rinsing three times with distilled water for 5 min each. These sections were then incubated in 3% hydrogen peroxide for 30 min at room temperature, heat-repaired with was as follows: 0 (-), 1 (+), 2 (++), and 3 (+++); the scoring of the percentage of positive staining was as follows: 0 (<5%), 1 (5-25%), 2 (26-50%), and 3 (>50%); and the total score=staining density score × staining percentage score. A total score ≥ 3 indicates positive protein expression, and a total score<3 indicates negative protein expression.
CellSearch TM CTC identification
The were considered as suspected CTC cells [9] .
CTC-biopsy
The mononuclear cell layer (approximately 2 mL) was obtained from the PB of patients by centrifugation at 1700 g for 20 min. Next, the cell suspension was centrifuged at 300 g for 15 min, followed by a third round of centrifugation at 300 g for 10 min. nucleus with an uneven coloration; cells that have a thickened nuclear membrane with dents or wrinkles; cells that show nuclear deviation or have large nucleoli.
Aggregates of >2 CTCs were identified as CTM [28] .
Statistical analysis
Statistical analysis was performed using SPSS 13.0 software (IBM, Chicago, IL, USA). Comparisons between groups were performed using the χ 2 test and Fisher's exact probability method. A value of P<0.05 was considered statistically significant.
Results
ISET method optimization
Large white blood cells such as monocytes and lymphocytes are difficult to filter using the ISET device. Hence, we designed two approaches to optimize the ISET device to reduce clogging issues: introducing pretreatment of the PB sample with an RBC lysis step to reduce RBC aggregation that can clog the filter membrane and increasing the pore size of the filter membrane from 8 μm to 10 μm. Tumor cells in the experimental group were stained CK + , CD45 -, and Hoechst + ; while leukocytes were stained CK -, CD45 + , and Hoechst + (Figure 3 ). Both tumor cells and white blood cells in the control group were stained CK -, CD45 -, and Hoechst + . Upon successful validation of the ISET-ICC system, we next evaluated its use for clinical testing using PB samples from 23 patients with advanced tumors and found that the CTC-positive rate was 65.2% (15/23) ( Table   2 ). Nine samples, which were stained CK + , CD45 -, and
Hoechst + , were identified as typical CTCs with a large cell volume and an abnormal nuclear-to-plasma ratio greater than 0.5 (Figure 4a );three samples, which were stained CK -, CD45 -, and Hoechst + , showed morphology characteristic of tumor cells and were identified as EMT-CTCs ( Figure 4b) ;
and three samples showing tumor cell aggregation (≥ 3 aggregated cells) and staining characteristic of both CTCs and EMT-CTCs were identified as CTM (Figure 4c ). 
No. Cancer type
patients diagnosed with late-stage tumors
Next, we wanted to validate the use of the ISET-ICC system with cell wax block IHC to identify EMT-CTCs in the PB from patients with advanced tumors ( Table 2) . EMT-CTCs (number ≥ 1) were detected in six samples (No. 2, 8, and 16; n=2) by the ISET-ICC method ( Table 2) , and subsequent wax block IHC revealed one twist-positive sample, two vimentin-positive samples, and no E-cadherin-positive samples ( Figure 5 ). Table 5 : Comparison of the cancer staging results from the three diagnostic methods. 
Performance of the ISET-ICC system for CTC detection
Performance of the CellSearch TM method for CTC detection
The CellSearch TM method detected 9 cases of CTCs out of the samples from 74 patients with various cancer types ( IV patients was significantly higher than that in patients with stage I-III (χ 2 = 6.76, p = 0.001) ( Tables 4 and 5 ). 
Performance of the CTC-biopsy method for CTC
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The CTC-biopsy method detected 14 cases of CTCs out of the samples from the 74 patients with various cancer types ( IV. There was no significant difference in the CTC detection rate for different cancer stages (χ 2 = 0.82, p = 0.103) (Tables 6).
Comparison of the ISET-ICC method with the
CellSearch TM and CTC-biopsy methods
The CTC-positive rate of the ISET-ICC method was 17.6% (13/74), which is between that of the CellSearch TM method (9/74, 12.2%) and the CTC-biopsy method (14/74, 18.9%) ( Table 4 ). We showed that the ISET-ICC method had a CTC-positive rate that was significantly different from that of the CellSearch TM method (χ 2 = 10.21, p = 0.007), but it was not significantly different from that of the CTC-biopsy method (χ 2 = 3.926, p = 0.062). Positive results were detected in all six cancer types, with a trend of a higher detection rate for the later stages for the CellSearch TM and ISET-ICC methods but not for the CTC-biopsy method.
Comparison of the diagnostic performance between the ISET and CellSearch TM methods based on specific cancer types revealed that they differed significantly for all cancer types except for lung cancer, while comparison between the ISET and CTC-biopsy methods showed that they differed significantly for all cancer types except for esophageal cancer.
Discussion
The ISET technology can overcome the issue of heterogeneity of surface marker expression, which is the primary problem of the FDA-approved CellSearch TM method [16] .In addition, ISET has been shown to have a higher CTC-positive rate compared with the CellSearch TM technology which is consistent with our findings [19, 32] . 
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The PB samples were mostly collected from patients who were in the fasting state or before treatment. Hence, there was an insufficient circulating blood volume and a relatively higher PB viscosity, which increases the tendency of the RBCs to adhere and aggregate [34] . This in turn leads to filter membrane clogging. Moreover, the larger white blood cells such as large lymphocytes have a reduced flexibility and become deformed after prefixation, which contributes to filter membrane clogging in the ISET device and gives rise to unreliable results [19, 29] . Thus, we added the [23, 37, 38] . The expression of EMT-related markers is higher than that of epithelial markers; hence, they can be used to more accurately monitor cancer prognosis [21] . However, the extent or proportion of EMT occurrence is not clear.
Thus, this heterogeneity of cell surface marker expression
reduces the diagnostic accuracy of marker-based detection methods.
In this study, we showed that the ISET-ICC system, but not the These findings suggest that the ISET-ICC system is a more robust method for CTC detection.
Since the CellSearch TM method is based on identifying enriched cells by their epithelial characteristics and can poorly detect antigenic properties, it is difficult to detect EMT-CTCs. This is the main reason for obtaining false negatives by the CellSearch TM method [16, 36] . The combination of fluorescent probe technology, such as fluorescence in situ hybridization, with the CellSearch TM method was validated for use in CTC detection, but it is difficult to apply it widely due to its high cost and poor compliance [39, 40] . By incorporating EMT markers for CTC identification in the ISET-ICC system, we resolved the issue of false-negative signals of the ICC method as CTCs capable of expressing EpCAM normally can be detected and identified. Hence, this confers a huge advantage over the FDA-approved CellSearch TM method. The use of cell wax blocks is an emerging technology in cytopathology for cytological detection of body fluid exfoliation, such as pleural effusion and serous effusion; this method has a high sensitivity and specificity [41] . IHC is a gold standard method for pathological diagnosis. Hence, the combined cell wax block-IHC method eliminates drawbacks such as the lack of a gold standard in cell morphology identification criteria and immunofluorescence quenching [42] . In this study, we combined the ISET-ICC technology with the cell wax block-IHC technique and verified its feasibility for use in EMT-CTC detection. However, the complex procedure of making the wax block, slicing, IHC staining, and the high cost, make this method unsuitable for clinical application.
The limitations of this study include the small clinical sample size of 74 patients, recruiting patients with numerous cancer types and different stages, and the manual operation of the ISET technique, which may have affected the obtained CTC-positive rate for all three detection methods tested. The tumor type has been shown to contribute to the diagnostic performance of the ISET and CellSearch TM methods [24] and this was consistent with our findings.
However, the inclusion of only six cancer types and the disproportionate sampling of each cancer type likely reduce the reliability of our results. The CTC-positive rates for the three methods tested were much lower than the previous comparison, which ranged from 20% to 60% depending on the cancer type [24] . This could in part be due to the disproportionate sampling of each cancer type and the small sample size used in this study. As our primary aim was to validate the preliminary use of the ISET-ICC technology for clinical CTC detection, we went ahead with a small sample size for this study. The low concordance and the observation of a minimal difference in the CTC-positive rate between the ISET-ICC and CTC-biopsy methods are likely due to the small sample size, which could have introduced bias. Hence, future research should use a larger sample size to reliably characterize the differences in the CTC detection rates among the diagnostic methods. Also, a larger sample size for specific cancers should be used to obtain a more reliable CTC-positive rate.
Conclusion
In conclusion, we showed that the developed two-step However, the small sample size of 74 patients used for the comparison study warrants further investigation with a larger sample size.
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